AKTS vs ALEC

Aktis Oncology, Inc. vs Alector, Inc. — Valuation Comparison 2026

AKTS

Biotechnology
Aktis Oncology, Inc.
Quality
1.6
out of 10
Value Trap
Price
$20.43
Last close
Models
8/13
Active
VS

ALEC

Biotechnology
Alector, Inc.
Quality
5.7
out of 10
Value Trap
32
LOW
Price
$2.15
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType AKTS Fair ValueAKTS Upside ALEC Fair ValueALEC Upside
Bayesian DCF Intrinsic $5.41 -73.5% $0.66 -69.4%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $3.75 -81.6% $0.93 -56.6%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $9.59 -53.0% $3.76 +74.7%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for AKTS vs ALEC — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

AKTS vs ALEC — Which Stock Is More Undervalued?

ALEC scores higher with a 5.7/10 quality rating vs AKTS's 1.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Aktis Oncology, Inc. (AKTS) and Alector, Inc. (ALEC) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

AKTS currently trades at $20.43 with a QOC of 1.6/10, while ALEC trades at $2.15 with a QOC of 5.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).